This article is more than 5 years old. Information may no longer be current.

Seven important updates for World Thrombosis Day

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

World Thrombosis Day is observed today to increase global awareness about the condition, including its causes, risk factors, symptoms, and prevention and treatment strategies.

In conjunction with this observation, HemOnc Today presents seven important updates in thrombosis treatment and detection.

• Inferior vena cava filters have become an increasingly popular tool to reduce risk for recurrent pulmonary emboli since their introduction 50 years ago. For this cover story, HemOnc Today spoke with researchers and hematologists about which patients most benefit from these filters, why device use and retrieval remain inconsistent, and whether new therapies may be safer alternatives for patients with elevated pulmonary embolism risk. Read more.
• An investigational, engineered therapy that mimics clotting enzyme ADAMTS-13 appeared effective and safe for patients with hereditary thrombotic thrombocytopenic purpura. Read more.
• Extensive cancer screening for individuals who experience unprovoked venous thromboembolism initially may detect more cancer cases than a limited occult screening approach. However, the difference in proportion of early-stage cancers detected by each approach did not reach statistical significance. Read more.
• Near-universal in-hospital prophylaxis did not lead to declines in hospital-related venous thromboembolic events. More than half of the nearly 500,000 VTEs that occur in the United States each year were related to current or recent hospitalization, but nearly 50% were unrelated. Read more.
• More advanced disease at the time of cancer diagnosis increased risk for venous thromboembolism. Read more.
• The FDA granted fast track designation to caplacizumab (Ablynx), a first-in-class anti-von Willebrand factor nanobody, for the treatment of acquired thrombotic thrombocytopenic purpura. Read more.
• Eculizumab (Soliris, Alexion Pharmaceuticals) reduced the presence of hemolysis, thrombosis and the need for red blood cell transfusions among patients with paroxysmal nocturnal hemoglobinuria. Read more.